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Before lysing an infected cell, CTL must first recognize a discrete viral protein
sequence in the context of a restricting protein of the MHC on the cell (1). CTL
playasignificant rolein terminatingviralinfection(2-9), andthe inabilityto generate
them can alter the outcome of viral invasion from an acute, self-limiting infection
to a persistent, continuous one (10). Adoptive reconstitution ofpersistently infected
hosts with previously primed virus-specific H-2-restricted CTLterminates the other-
wise life-long infection (11). Yet, despite the role ofCTL in influencing the outcome
ofinfection, except primarily forstudieswith influenzavirus(12-16), relatively little
is known about the precise protein sequence(s) that CTL recognize, especially gly-
coproteins, and their relationship to restriction elements within the MHC.
To define the molecules involved in CTL recognition, we chose the model oflym-
phocytic choriomeningitis virus (LCMV)' in mice for several reasons. LCMV is
a natural pathogen ofmice (17), and the genetics ofthe mouse MHC is well under-
stood and easily manipulated (18). CTL specific for LCMV are readily obtained
and constitute a majorimmune response in vivo forterminating acute infection (2,
5, 17). Their absence is associated with persistent infection (1, 2, 11). Hence, data
obtained from in vitro experimentation can be tested in vivo within a natural host-
virus model.
LCMV has two RNA segments, a large (L) one of -7.5 kb and a short (S) seg-
ment of 3.3 kb; CTL induction and recognition map to proteins encoded by genes
on the S RNA (19, 20). The S RNA of LCMV Armstrong (ARM) encodes a 498
amino acid (aa) glycoprotein (GP)from its 5' ORFthat is posttranslationally cleaved
at residues 262-263 to yield GP-1 (aa 1-262) and GP-2 (aa 263-498) and a 558-aa
nucleoprotein (NP) made from the 3' ORF (21,22). Earlier studies using cDNAs
ofLCMV GP or LCMV NP expressed in vaccinia virus (23, 24) indicated that the
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H-2-restricting haplotype selected different LCMV proteins for CTL recognition
epitopes and that the GP in H-2b mice induced a prominent (N33% of the total)
CTL response (23). Further dissection of the GP recognition sites in H-2b
(C57BL/6) mice using a series of LCMV ARM GP cDNA deletions from the 3'
end indicated that the vast majority of H-2b LCMV CTL clones (17 of 18 : 94%)
recognized GP, and 1 (6%) NP (23, 24). Further, the majority of GP CTL clones,
15/17 (88%), recognized targets expressing GP as 272-293 (Table I). Here we re-
port using five of these CTL clones, 232, 228, 31, RG-9, and 39, a battery of trun-
cated peptides from GP as 272-293 region, and site-specific amino acid substitu-
tions to precisely identify and map the fine structure of the CTL epitope.
Materials and Methods
Target Cells, Viruses, andMouse Strains.
￿
BALB/c clone (Cl) 7 (K'IdDd), B10.3R (KbIbD'),
B10.4R (KkIkDb), and B10.5R (KllbDd) cells were grown in MEM supplement with 10%
heat-inactivated FCS, 104 U of penicillin/ml, 10 mg of streptomycin/ml, and 1 MM r.-
glutamine, while MC57 (KbIbDb) cells were grown in RPMI 1640 supplemented as above.
Viruses used have been described previously (11, 23, 24) and consisted ofLCMV ARM clone
53b, recombinant vaccinia virus:LCMV GP cDNA vectors expressing LCMV GP as 1-363,
1-293, 1-271, 1-218, and vaccinia virus:LCMV NP cDNA vectors expressing LCMV NP
1-558. BALB/WEHI (W) (H-2d) and C57BL/6 (H-26) mice were obtained from the closed
vivarium breeding colony at the Research Institute of Scripps Clinic.
CTL Clones.
￿
Specific CTL clones (H-26) were generated from C57BL/6 mice and main-
tained in culture as previously detailed (24). CTL clones were virus specific in that they failed
to lyse target cells infected with vaccinia virus alone and H-2 restricted as they lysed H-26
but not H-2d targets infected with LCMV The specificity of the clones used for experimen-
tation are shown in Table I . CTL clones were used in E/T ratios of 5 :1 and 2.5:1.
PrimaryDay 6-7Splenic CTL.
￿
LCMVspecific CTL were induced by intraperitoneal in-
jection of 2 x 105 PFU of virus. Spleens were harvested 6-7 d after inoculation. Primary
vaccinia CTL were induced by intraperitoneal inoculation of 2 x 106 PFU of virus, with
harvesting on the 6th day. Single cell suspensions, free of erythrocytes, were used at E/T
ratios of 50:1 and 25:1 (11, 24).
Cytotoxic Assays.
￿
Killing by CTL was quantitated using a 4-5-h "Cr-release assay as de-
scribed (11, 24). Target cell numbers used per assay point were 2 x 104. Samples were
processed in triplicate and standard deviation among triplicates was <7%.
Peptide Synthesis.
￿
Peptides were synthesized by the solid phase method described by
Merrifield (25) with an automated peptide synthesizer (model 430A; Applied Biosystems,
Inc., Foster City, CA) or by the tea bag method of Houghten (26). Peptides were cleaved
from their insoluble polystyrene resinbeadsbyhydrogen fluoride, extracted, lyophilized, and
analyzed for purity by HPLC. Unless stated otherwise in the text, peptide, solubilized in
RPMI, was incubated at a final concentration of 200 gg/ml with uninfected target cells
throughout the 4-5-h period of the cytotoxic assay.
Results
A Major Lymphocytic Choriomeningitis Viral Epitope Restricted by H-26 Haplotype Resides
in the Glycopmtein between as Residues 272-293. A peptide encompassing LCMV ARM
GP as 272-293 I.SDSSGVENPGGYCLTKWMILA was synthesized, and its ac-
tivity was analyzed. When 200 pg/ml of peptide was used to coat H-2b cells, these
targets were lysed in an LCMV peptide-specific and H-2-restricted manner by LCMV
CTL clones (specific "Cr released by clone 232: 62%, by clone 228: 40%) that
recognize the major GP CTL epitope but not by the CTL clone (2-1 : 7 %) that recog-OLDSTONE ET AL.
TABLE I
Characteristics of CTL Clones Used
561
In brief, the LCMV GP gene was serially truncated from the Tend and attached to translational termination
sequences. The restriction enzymes used were Bgl II, Pst I, Tthl III, and Dra III which, respectively, generated
COOH terminally truncated GP molecules comprising residues 1-363, 1-293, 1-271, and 1-218. These cDNA
clones, and a full-length LCMV NP clone, were introduced into vaccinia virus by standard methods. In
all cases, Northern blot analyses have confirmed the expression from the recombinant vaccinia of LCMV-
specific RNA of appropriate size and polarity. All recombinants express abundant LCMV polypeptide as
judged by fluorescent antibody detection . For details see references 23, 24.
nizes LCMV NP The fact that CTL clones 232 and 228 lysed uninfected H-2b
targets coated with peptide as 272-293 as efficiently as H-2b targets infected with
LCMV further confirmed that this peptide sequence contained the viral epitope
being recognized by these clones. Results with CTL clones 31, RG-9, and 39 were
similar (data not shown). The finding that primary splenic CTL gave lower values
for target cells coated with peptide as 272-293 when compared with target cells in-
fected with virus indicated that bulk CTL recognize other viral epitopes. For ex-
ample, specific lysis by H-2b splenic CTL on peptide-coated H-2b target was 26%
as compared with 68% for LCMVinfected target. In contrast, H-2a splenic CTL
failed to lyse~-I-2b targets either coated with peptide or infected with LCMV These
observations were recorded in over five separate experiments. When H-2b targets
were coated with non-LCMV peptides, no lysis occurred.
Todetermine theminimal amount ofas272-293 required tocoat targets forCTI,
activity, log dilutions of peptide were made, incubated with uninfected "Cr-labeled
H-2b targets, and reacted with either CTL clones 232 or 228. Results of these ex-
periments indicated that half-maximal lysis is achieved with 0.5 ug/ml of the pep-
tide (concentration: 0.25 pM).
The Minimal as Sequence of LCMV Viral Epitope Restricted by H-2b Haplotype is GP
278-286 VENPGGYCL. With a major viral epitope identified in as 272-293, a set
of 12 peptides was synthesized (upper 12 peptides, Fig. 1) that contained single as
deletions from the NH2 or COOH termini. 40 ug ofeach peptide was used to coat
H-2'-uninfected targets, which were then reacted with CTL clones 232 or 228, and
the "Cr released was quantitated. Both clones gave equivalent results, indicating
that removing as 272-276 or 288-293 had no effect on the efficiency ofCTL ac-
H-26 syngeneic target cells inoculated with:
Vector:LCMV expression
CTL clones
reactive/total
Percent 5 'Cr release with H-26
syngeneic effector CTL clones :
232 228 31 RG-9 39 2-1
LCMV arm 18/18 47 60 55 66 37 41
Vaccinia/GP1 as 1-262 + GP2 as 263-363 17/18 49 52 43 55 22 0
Vacclnia/GPI aa 1-262 + GP2 as 263-293 17/18 52 55 41 59 28 8
Vaccinia/GPI as 1-262 + GP2 as 263-271 2/18 0 0 0 15 9 9
Vaccinia/GPI as 1-218 2/18 0 0 0 12 ND 5
Vaccinia/NP as 1-558 1/18 0 0 0 0 2 36
Vaccinia/NIL 0/18 0 0 0 0 10 0
Non-H-2 restricted (H-2d targets)
LCM virus 0/18
Vacclnla/GPI aa 1-262 + GP2 as 263-293 0/18 Lysis by H-2d
Vaccinia/GP1 as 1-262 + GP2 as 263-272 0/18 Bulk splenic CTL: 67%562
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tivity. Thus, peptideas 277-287, GVENPGGYCLT-coated cells were lysed equiva-
lently with corresponding targets coated with as 272-293 (Fig. 1). When THR in
position 287 was removed, lysis occurred but at roughly halfthe value (35% com-
pared with 65% specific "Cr release). When LEU in position 286 was removed,
lysis was abolished. Repeated studies confirmed these observations. In otherexperi-
ments, six additional peptides were generated (lower six peptides, Fig. 1) and their
activity on targets with CTL clones showed that deletion ofGLY from position 277
did not abrogate lysis (percent specific lysis by CTL clones 228, 232 GVENPG-
GYCLT: 58%, VENPGGYCLT 61%), whereas removal ofVAL from as position
278 (ENPGGYCLT: 3%) did. Thus the minimal epitope mapped comprises nine
aa, 278-286 VENPGGYCL (Fig. 1).
Site-speck Substitution in as Position 278 Defines Three Sets ofCTL Clones.
￿
The next
series ofexperiments used five CTLclones to focuson the fine structure ofthe viral
epitope forCTL recognition. Since the previous studies indicatedthat VAL in posi-
tion 278 was critical forCTL recognition ofthe viral epitope, a series ofamino acid
replacements at as 278 were made to dissect peptide-directed CTL activity. As seen
in Table II, conservative as substitutions in position 278 VAL to ALA, LEU, or
ILE did not alter CTL activity of any ofthe five clones. Substitution to GLY main-
tained the activity but at a lesser degree. From these as replacements it isclear that
these CTL clones prefer hydrophobic residues. Similarly, substitution ofVALto ASN
resulted in only minor alterations in CTL lysis while change ofVAL to LYS dimin-
ished killing by CTL clone 228 to a much greater extent than the other four CTL
clones. Substitution ofVALto ASP orGLU diminished CTL activity in CTL clones
232, 31, RG-9, and 39while totally abrogating responseofCTL clone 228. Interest-TABLE II
Finer Specicities of Five-CTL Clones that Recognize GP as VENPGGYCL
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Fine specificities for CTL recognition. A series of peptides 272-293 were syn-
thesized with single amino acid substitution in position 278 where VAL (V) was
substituted for LEU (L), ILE (I), ALA (A), GLY (G), SER (S), THR (T), PHE
(F), TYR (Y), ASP (D), GLU (E), LYS (K), or ASN (N) as described (26).
Individual peptides at final concentration of 200 wg/ml were added to 2 x 104
5'Cr-labeled H-2b or H-2d uninfected target cells. Cells were then incubated with
either CTL clones 232, 228, 31, RG-9, or 39 (E/T ratio 2 .5:1) for 4-5 h, and
specific 5'Cr release was quantitated. Lysis was restricted to H-2b targets (not
H-2d) with specific release of 40-60% for CTL clones reacted with the native
as sequence (i.e., VAL in position 278).
ingly, the CTL activity of clone 39 could be segregated from clones 232, 31, and
RG-9 by amino acid substitutions that added aromatic amino acids in position 278.
Thus, when aromatic amino acids were added as indicated by substitution ofTYR
orPHE forVAL, CTL clones 232, 31, and RG-9 retained theirlytic activity, whereas,
in contrast, CTL clone 39 totallylost activity. Similarly, when TYR orPHEreplaced
VAL or if a change in polarity occurred (substitution of SER or THR for VAL),
CTL clone 228 lost total activity.
We then assayed the ability of CTL clones to lyse H-2b-uninfected target cells
coated with concentrations ofLCMV GP peptide at 12.5, 50, or 200 ug/ml. As seen
in Fig. 2, significant lysis by CTL clones 228 and 232 occurred over a wide dose
range (from 12.5 to 200 pg/ml) with the majority ofpeptide-coated targets (Fig. 2).
An exception was thelysis by CTL clone 232 oftargets coated with LCMV GP pep-
tide containing either SER or THR in residue 278. In this instance lysis occurred
at 200 but not 50 or 12.5 wg/ml concentrations.
The Viral Epitope Recognized by H-26 is Class I MHC Restricted to Db, not Kb; and H-
2Db al as 37-52 Peptides Block CTL Lysis. Afinal series of experiments dissected
the H-2b haplotype's contribution to CTL lysis using CTL clones 232 and 228.
Results with target cells recombinant at the class I and class II MHC loci indicated
that lysis was restricted to Db, and not Kb or Ib. Hence, recombinant target B10AR
K1IkDb cells were lysed as efficiently as the nonrecombinant KbIbD' targets, whereas
B10.3R and B10.5R both containing Kb and Ib are not lysed (Table III). Db haplo-
Substituted amino acid
278 232
% Specific
31
lysis by
RG9
CTL clones
228 39
. . . GVENPGGYCL . . . 100 100 100 100 100
L 100 97 80 87 99
1 100 75 84 100 61
A 100 78 67 100 100
G 38 ND ND 38 ND
S 62 100 95 2 53
T 33 86 91 2 75
F 70 79 67 1 <1
Y 96 34 23 2 <1
D 16 21 10 2 13
E 43 20 21 1 10
K 91 77 85 13 100
N 97 86 100 100 100564
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FIGURE 2.
￿
Dose-response analysis of thepeptides used to map fine specificities of CTL recogni-
tion. A series of peptides 272-293 was synthesized with single as substitution in position 278
where VAL was replaced with LEU, ILE, ASN, SER, THR, PHE, or TYR as described (26).
Individual peptides at finalconcentrations of 200, 50, or 12 .5 Pg/mlwere added to 2 x 104"Cr-
labeled H-26-uninfected target cells or 200 ug/ml added to 2 x 10451Cr-labeled H-2d uninfected
target cells. Cells were then incubated with either CTL clone 232 or 228 E/T ratio 2.5:1) for
4-5 h, and specific "Crreleasewas quantitated. Lysis was restricted to H-26 targets (not H-2d)
with specific release of 45% and 49% for CTL clones 228 and 232 reacted with native as se-
quence (i.e., VAL in position 278).
types also contain Lb class I molecules that cannot be separated by these ex-
periments.
Comparison of LCMV GP epitope as 272-293 with Db and Kb sequences (Lb
has not yet been sequenced) stored in the Dayhoffdata bank indicated regions of
homology with Db and Kb a1 amino acid sequence 37-52 (Fig. 4).
Corresponding Db and Kb peptides were synthesized, purified by HPLC (>90%
pure), and studied to see whether they interfered with Lysis of H-2b-uninfected
targets coated with LCMV GP as 272-293 or infected with LCMV ARM. As seen
in Fig. 4, H-2Db al as 37-52 blocked Lysis in a dose-response manner, but the cor-
responding Kb peptide that differs from Db by substitution ofARG for PRO in res-
FIGURE 3.
￿
Comparison of LCMV GP
epitope as 272-293 with Db and Kb se-
quences stored in the Dayhoffdata bank.
LCMV GP 274 DSSGVENPGG_YCLTK WM
Db al 37 MD A$Np RfEPRAPt'vM
Kb al 37 DSD A$fiII' RYEPRARO1$CTL clones at effector to target (E/T) ratios of5:1 or 2.5:1 were used in a 5-h 51Cr-release assay as described
(10, 11). Numbers represent mean values for triplicate samples. Variance was <10% .
idue 50 did not. These results were confirmed in several independent experiments.
The Db peptides also blocked killing of H-26 splenic CTL, although some of these
are Kb restricted (27).
Discussion
These studies provide a detailed fine structural map of a major LCMV ARM
glycoprotein epitope recognized by H-26-restricted CTL. The epitope comprises the
LCMV GP'
￿
274 DSSGVENPGGYCLTK WM
Db a chain 37 DSD AENP RYEPRAPWM
Kb a chain
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CTL Killing Is Restricted to Class IMHC Db
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FIGURE 4.
￿
Db peptide containing residues 37-52 from al domain blocks lysis of H-26 targets
coated with LCMV ARM GP as 272-293 by CTL clone 228 or of LCMVinfected cells by bulk
splenic CTL. CTL clones (5 x 104 cell; E/T ratio 2.5:1) or bulk splenocytes 106 cells; E/T 50:1)
were incubated with varying final concentrations of Db or corresponding Kb peptide (2,500; 2,000;
1,500; 1,000; 500, 2501tg/ml). After a 30 min incubation at 37°C the mixture was added to 51Cr-
labeled uninfected MC57 cells coated with LCMV ARM peptide at 200 pg/ml and specific lysis
was calculated. Similar results were observed with CTL clone 232.
Percent 51chromium released from
Effector
CTL
Ratio
E/T
MC57
LCMV
KbIbDb
UNINF
B10.3R
LCMV
KbIbDd
UNINF
B10AR
LCMV
KkIkDb
UNINF
B10.5R
LCMV
KbIbDd
UNINF
Clone 232 5:1 83 5 5 8 90 8 7 5
2 .5:1 84 1 2 1 56 1 4 4
Clone 228 5:1 63 - 1 1 72 3 3 2566
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linear amino acid sequence VENPGGYCL, as 278-286 ofLCMV ARM GP, and
its recognition is restricted by the class I H-2 Db gene product. The structure of
this peptide bound toatarget or within the native protein expressed on virus-infected
cells is unknown. Nevertheless, theprevalence ofGLYresidues coupledwith a PRO-
GLY is most consistent with a R turn and unlikely to be an a-helical structure (28).
Hence, the current predictive schemes involving an amphipathic a helix (29, 30)
as used for T helper lymphocyte epitopes are not consistent with the experimental
data obtained here and thus may be oflimited value for CTL predictions. An alter-
native scheme (31) required hydrophobic residues flankedby GLY, charged or polar
moieties. This motif is not found in the nine-aa epitope found for LCMV GP al-
though itwashelpful forpredictingaCTL-influenza virus matrix protein(16). Clearly
more epitopes need to bedefined and analyzed before workable rules can be devel-
oped forauniversallyhelpfulprediction scheme. Theapproaches reported herecoupled
with studies in otherviralsystems (13-16, 32-34) should supply the background data
required. Interestingly, the viral epitope we mapped according to normalized fre-
quencies of occurrence ofas residues in secondary structure (28) suggested a likely
R turn, as did as in position 281-283 that contained PRO-GLYGLY, which corre-
sponds to similar sequences observed by the nuclear magnetic resonance studies of
Dyson et al. (35, 36) for the formation ofreverse turn ofpeptide fragments ofpro-
teins in water solution.
Amajor function of protein(s) encoded by the MHC is to bind selectively to a
part of a viral (foreign) antigen, thereby making it recognizable to CTL. Analysis
ofthe three-dimensional structure ofthe human HLA A2 molecule (37, 38) suggests
that an MHC molecule has a single binding site for foreign antigen. Within the
MHC structure is a groove 25 A long, 10 A wide and 11 A deep capable ofaccom-
modating a peptide of 8 to 15 or 16 as in length. The nine-aa epitope described
here would fit into that size cavity.
To address the paradox of how a few MHC molecules might be able to handle
a large repertoire ofviral antigens, several investigators have proposed the existence
ofmeaningful sequencehomology betweentheforeign viralprotein and MHC binding
site (39-41). Accordingly, we found homology between the MHC H-2D6 restric-
tion molecule in the al domain residues 37-52 and the H-2Kb nonrestriction mol-
ecule in the same location with LCMV GP 274-291. After adding spacers in the
MHC molecules between residues 39-40 and 43-44, an alignment occurred where
the minimal LCMV CTL epitope VENPGGYCL contained homologous residues
-XENP-XY. The Db peptide 37-52 differed from the Kb peptide by one amino acid
in position 50 PRO - ARG and blocked CTL killing, while the Kb peptide did
not. However, these results did not explain the observations that H-26 splenic CTL
(some ofwhich are Kb and perhaps Lb restricted) are effectively blocked and that
the single as substitution between Kb and Db maps a few as upstream from the viral
epitope (Fig. 3). Further, the H-26 peptide maps close to but outside the cavity be-
lieved to be the HLA-A2 antigen binding site (37, 38). Conceivably, the activity of
the PRO in position 50 of H-2Db may provide a conformational change that em-
powers this peptide to inhibit competitively viral peptide binding to H-26 MHC
molecules expressed on the cell surface. The binding affinities ofthese peptides are
not known nor is their mode of action. Presumably the affinity ofthe H-2D6 pep-OLDSTONE ET AL.
￿
567
tide is higher than that of H-2K6, thereby enabling the former to block recogni-
tion of the critical MHC molecule by CTL.
Where and howcells bind peptides is uncertain. It is unlikely thatTlymphocytes
recognizeforeign antigens asnatural three-dimensional structures (12). The mecha-
nism by whichsuchproteins aredegraded into shortpeptides and thecellular pathways
they undertake to reach the cell's surface is unclear. Recentlyavaccinia/LCMVcDNA
expressing the short peptide as 272-293 was constructed and used to infect H-2b
cells. Thesecells processed the truncated protein internally, afterwhichitwasrecog-
nized byCTL clones 228 and 232 as efficiently asthe synthesizedLCMV GP 272-293
as peptideaddedexogenously (Whitton,J. L., M. B. A. Oldstone, unpublished data).
Mapping the pathwaysofthese exogenous and endogenous viral reagents within target
cells and determining where they associate with MHC may illuminate this problem.
Finally, CTL have a fine specificity allowing discrimination at the single as level.
For example, the five CTLclones analyzed here were defined on the basis ofsimilar
recognition of the major LCMV glycoprotein epitope restricted by H-26. The size
of the nine-aa viral epitope and the ability of a single as deletion from the native
structure either at the NH2 or COOH termini suggest that a single interaction with
D'' occurred. Yet, the specificities of the clones could be further distinguished by
selective as substitutions in position 278 that altered the recognition epitope. Thus,
addition ofpolar side chains by substituting SER or THR forVAL segregated these
clones into two functional groups. Further, addition ofaromatic acids by substitu-
tion ofPHEorTYR forVAL further segregated thesepermissive CTLclones func-
tionally. Dose-response analysis ofsubstituted peptides, especially hydrophobicones,
failed to alter the established recognition pattern even using peptides at 12.5 wg/ml
concentration. Fine CTL specificity has been noted previously by Bastin et al. (15)
for influenzavirus nucleoprotein where a substitution ofASP toGLU in asposition
372 aborted class I CTL clone F5 lysis. However the 15-aa size ofthepeptide epitope
was not sufficiently mapped to ascertain whether a single or multiple site ofinterac-
tion with MHC occurred. Nevertheless, those data and ours strongly suggest that
fine CTL specificity appears similar to that exhibited by mAbs and T helper cells
(42) as regards recognition of single as changes. The discrimination by these CTL
clones will likely be reflected in analysis oftheir corresponding CTL receptors. We
are currently pursuing such studies with CTL clones reported here.
Summary
We define a nine-amino acid (aa) sequence ofVAL-GLU-ASN-PRO-GLYGLY
TYR-CYS-LEU as a major epitope for immunologic recognition of lymphocytic
choriomeningitis virus (LCMV) by H-2'-restricted CTL. The epitope was charac-
terized using molecular genetics to bracket broadlyand chemistry to precisely iden-
tify as residues 278-286 ofthe viral glycoprotein. The epitope's compostion is char-
acteristic ofa reverse (R turn) but not an amphipathic a helix. A series ofpeptides
with a single as substitution in position 278 of VAL with other nonpolar (hydro-
phobic) amino acids (LEU, ILE, ALA, or GLY) coat targets that are recognized
and lysed by CTL clones recognizing this epitope. In contrast, substitution ofVAL
with either large aromatic amino acids (that add bulk: PHE, TYR) or polar side568
￿
FINE DISSECTION OF A NINE AMINO ACID EPITOPE
chains (SER, THR) segregates CTL clones normally recognizing as 278-286 into
two groups, one that remains lytic (permissive) despite these changes and another
that fails to lyse, indicating CTL can discriminate at a single aa. A change in charge
at this position (VAL - ASP or GLU), in general, reduces CTL lysiswhile a change
of VAL to LYS or ASN has minimal affect for four of the five CTL clones analyzed.
CTL reactivity with the viral epitope is restricted by the Db but not the Kb of the
murine MHC haplotype. A 16-aa peptide of Db that spans al residues 37-52 blocks
CTL lysis, whereas the corresponding Kb peptide that differs from Db in a single
as in position 50 does not.
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